Two years later, a larger-scale Phase II clinical trial was conducted, Patients with advanced PD-L1-positive ovarian cancer were stratified, and their objective response rate (ORR) was evaluated based on the combined positive score (CPS) of PD-L1 expression (46). This evidence concerns the gene CD274 and ovarian carcinoma.